Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Announces Presentations on Lead PD-1 and HER-2 Cancer Vaccines at the American Association for Cancer Research 2019 Annual Meeting

SYDNEY, Australia, 4 March 2019: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced Dr Tanios Bekaii-Saab from the Mayo Clinic will present on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

The presentations will be presented by Dr Saab, the co-inventor of the KEY-Vaxx and B-Vaxx cancer vaccines with Professor Pravin Kaumaya, and member of the Company’s Scientific Advisory Board, at the AACR Annual Meeting in Atlanta, Georgia scheduled for March 29 to April 3, 2019.


For further information please download PDF attached:
Download this document